Cognition

SAVA 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm’s Attorneys Now, Oct. 26th Deadline in Securities Class Action

Sunday, October 24, 2021 - 6:00pm

The petition raised serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.

Key Points: 
  • The petition raised serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.
  • The petition further identified errors and anomalies in the data of a sufficient frequency and magnitude to strongly suggest scientific misconduct.
  • Were focused on investors losses and proving Cassava manipulated clinical data for simufilam, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

CASSAVA DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their Options

Sunday, October 24, 2021 - 1:29pm

If you suffered losses exceeding $100,000 investing in Cassava stock or options between February 2, 2021 and August 24, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Cassava stock or options between February 2, 2021 and August 24, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassavas conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

SHAREHOLDER ALERT: CASSAVA SCIENCES, INC. (NASDAQ: SAVA) OCTOBER 26, 2021 CLASS ACTION LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava

Saturday, October 23, 2021 - 2:30pm

The lawsuit filed in the United States District Court for the Western District of Texas alleges violations of the Securities Act of 1934.

Key Points: 
  • The lawsuit filed in the United States District Court for the Western District of Texas alleges violations of the Securities Act of 1934.
  • The petition raises serious concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate.
  • On this news, the price of Cassava shares fell almost 32%, declining approximately $37 per share per share on August 24, 2021.
  • If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2021.

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Friday, October 22, 2021 - 1:22pm

BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced today that it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor (HGF) at its receptor, MET, which are expressed in the central nervous system to promote brain health and function. Athira expects to report topline results from the trial in the first half of 2022.

Key Points: 
  • We look forward to building on this momentum and sharing topline results from this Phase 2 trial in the first half of 2022.
  • The completion of enrollment in ACT-AD is an important clinical milestone for Athira.
  • By focusing on neuronal network recovery, ATH-1017s novel mechanism of action is agnostic to the underlying disease pathology of Alzheimers and other dementias.
  • Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimers and Parkinsons disease dementia.

ZERO Announces Apollo, its Latest AI-Driven Productivity Automation Tool for the Legal Industry

Thursday, October 21, 2021 - 6:30pm

CAMPBELL, Calif., Oct. 21, 2021 /PRNewswire/ -- ZERO, a pioneer in productivity automation solutions for professional services firms, today announced the launch of Apollo, a new software solution that automatically captures lawyers time spent on billable work on any desktop device and seamlessly integrates it into their existing billing platform. Apollo is a low-touch, high-impact solution that can be deployed seamlessly on a law firm's existing IT infrastructure.

Key Points: 
  • Apollo is a low-touch, high-impact solution that can be deployed seamlessly on a law firm's existing IT infrastructure.
  • ZERO is well-known in the legal industry via partnerships with AMLAW500 companies automating their internal administrative processes, like billing, email, and document management.
  • ZERO is a leader in Productivity Automation with products engineered to help professional services firms achieve operational excellence.
  • Law firms around the world rely on ZERO to minimize revenue leakage, increase email compliance, and improve the lives of their lawyers.

ZERO Announces Apollo, its Latest AI-Driven Productivity Automation Tool for the Legal Industry

Thursday, October 21, 2021 - 6:30pm

CAMPBELL, Calif., Oct. 21, 2021 /PRNewswire/ -- ZERO, a pioneer in productivity automation solutions for professional services firms, today announced the launch of Apollo, a new software solution that automatically captures lawyers time spent on billable work on any desktop device and seamlessly integrates it into their existing billing platform. Apollo is a low-touch, high-impact solution that can be deployed seamlessly on a law firm's existing IT infrastructure.

Key Points: 
  • Apollo is a low-touch, high-impact solution that can be deployed seamlessly on a law firm's existing IT infrastructure.
  • ZERO is well-known in the legal industry via partnerships with AMLAW500 companies automating their internal administrative processes, like billing, email, and document management.
  • ZERO is a leader in Productivity Automation with products engineered to help professional services firms achieve operational excellence.
  • Law firms around the world rely on ZERO to minimize revenue leakage, increase email compliance, and improve the lives of their lawyers.

Total Brain Brings New Clinical Platform to the Behavioral Health and Addiction Treatment Markets; Offers Game-Changing Stress Management Tools

Thursday, October 21, 2021 - 3:07pm

SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ --Total Brain, a mental health and brain performance self-monitoring and self-care platform, has launched a new and improved clinical platform for the behavioral health and addiction treatment markets.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ --Total Brain, a mental health and brain performance self-monitoring and self-care platform, has launched a new and improved clinical platform for the behavioral health and addiction treatment markets.
  • The Total Brain clinical platform includes a clinically-validated assessment, mobile app-based self-care tools, and a clinician dashboard.
  • The new Total Brain clinical platform is in response to clinicians asking for a robust set of actionable data.
  • Total Brain is a mental health and brain performance self-monitoring and self-care platform that has more than 1M registered users.

San Francisco Campus for Jewish Living and UCSF Expand Partnership

Thursday, October 21, 2021 - 1:47pm

SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ --The Jewish Home & Rehab Center (JHRC) on the San Francisco Campus for Jewish Living (SFCJL) has embarked on an extraordinary new organization change to its medical care and oversight.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ --The Jewish Home & Rehab Center (JHRC) on the San Francisco Campus for Jewish Living (SFCJL) has embarked on an extraordinary new organization change to its medical care and oversight.
  • A new JHRC UCSF Partnership in Geriatric Medicine provides integrated and coordinated delivery of clinical care expertise in geriatrics and palliative care across UCSF and SFCJL's post-acute rehabilitation, expanding the reach of UCSF geriatricians in our community.
  • Together, this community-academic partnership enhances the care of our community's most complex patients by integrating geriatric models of care with education and research.
  • Dr. Yukawa is a geriatric medicine specialist and Professor in the UCSF Division of Geriatrics.

reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

Thursday, October 21, 2021 - 12:00pm

The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.

Key Points: 
  • The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.
  • To date, healthy volunteers in the SAD phase have been dosed up to 700 mg, and food impact has been assessed at this high dose.
  • The preclinical studies and early clinical trials of ReS19-T provide a strong foundation for advancing this innovative treatment.
  • With this promising data we are getting close to a pivotal test of the calcium hypothesis in patients in 2022.

Huntkey Was Invited to Observe the on-Site Launch of Tianzhou-3

Thursday, October 21, 2021 - 3:23am

Against this historical background, Huntkey Group, which helped the development of the aerospace industry, was invited to the Wenchang aerospace launch site in Hainan Province to observe the launch of Tianzhou-3.

Key Points: 
  • Against this historical background, Huntkey Group, which helped the development of the aerospace industry, was invited to the Wenchang aerospace launch site in Hainan Province to observe the launch of Tianzhou-3.
  • Mr.Liu was deeply moved and said that Huntkey would consistently make unremitting efforts for the development of the aerospace industry.
  • Huntkey is an Asia renowned brand, a member of The International Power Supply Manufacturer's Association (PSMA) and China Power Supply Society (CPSS).
  • For more information visit https://en.huntkey.com
    In 2020, Huntkey introduced its latest photocatalyst air purifier - the desktop air purifier globally.